Title: Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Journal: Journal of Crohn's & colitis 20130901
Title: Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action.
Journal: The Journal of pharmacology and experimental therapeutics 20120901
Title: Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation.
Journal: Transplantation 20120615
Title: Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Journal: Arzneimittel-Forschung 20110101
Title: 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
Journal: Inflammatory bowel diseases 20101001
Title: New preclinical findings with vidofludimus.
Journal: Immunotherapy 20100701
Title: 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
Journal: The American journal of pathology 20100601
Title: Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20060115
Title: SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20051101
Title: Fitzpatrick LR, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60.
Title: Fitzpatrick LR, et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2010 Oct;16(10):1763-77.
